ADCC
MCID: ADR016
MIFTS: 61

Adrenal Cortical Carcinoma (ADCC) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Cardiovascular diseases, Nephrological diseases, Reproductive diseases, Endocrine diseases

Aliases & Classifications for Adrenal Cortical Carcinoma

Aliases & Descriptions for Adrenal Cortical Carcinoma:

Name: Adrenal Cortical Carcinoma 54 39 12 13
Adrenocortical Carcinoma 39 12 50 56 66 29 42 14 69
Adrenocortical Carcinoma, Hereditary 54 69
Hereditary Adrenocortical Carcinoma 66 29
Pediatric Adrenocortical Carcinoma 66 29
Carcinoma of the Adrenal Cortex 12 29
Malignant Neoplasm of Adrenal Cortex 69
Adrenocortical Carcinoma, Pediatric 69
Carcinoma Adrenocortical 52
Adrenocortical Cancer 52
Adcc 66
Acc 50

Characteristics:

Orphanet epidemiological data:

56
adrenocortical carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood;

HPO:

32
adrenal cortical carcinoma:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 54 202300
Disease Ontology 12 DOID:3948
MeSH 42 D018268
NCIt 47 C9325
SNOMED-CT 64 2227007 255035007
Orphanet 56 ORPHA1501
MESH via Orphanet 43 D018268
ICD10 via Orphanet 34 C74.0
UMLS via Orphanet 70 C0206686
ICD10 33 C74.0
UMLS 69 C0206686

Summaries for Adrenal Cortical Carcinoma

NIH Rare Diseases : 50 adrenocortical carcinoma is a rare cancer affecting the outside of the adrenal glands (adrenal cortex). these glands are on top of each kidney and are responsible for producing certain hormones and keeping blood pressure at normal levels. adrenocortical carcinoma is relatively frequent in children compared to many other cancers, although the cancer may also affect adults. girls are more often affected than boys. symptoms of adrenocortical carcinoma may include pain in the abdomen, hypertension, weight gain, frequent urination and possibly deepening of the voice. these symptoms are due to the tumors causing excess secretion of hormones from the adrenal glands. adrenocortical carcinoma may develop by chance alone, but at least 50% of the cancers are thought to be hereditary. there are a number of genes that have changes (mutations) that can cause an adrenocortical carcinoma, including tp53 and igf2. there have been reports of both autosomal dominant inheritance and autosomal recessive inheritance. an adrenocortical carcinoma is diagnosed based on urine tests for abnormal levels of cortisol, the hormone released by the adrenal glands. blood tests can also be conducted to measure levels of potassium and sodium in the blood. a ct scan or mri may be used to search for a visible tumor in the adrenal cortex. treatment options include surgical removal of the tumor, which is important to achieve a good long-term outlook. chemotherapy, specifically a drug called mitotane, can be used to try to remove any remaining cancer after surgery.  last updated: 9/8/2016

MalaCards based summary : Adrenal Cortical Carcinoma, also known as adrenocortical carcinoma, is related to adrenocortical carcinoma with pure aldosterone hypersecretion and adrenal carcinoma, and has symptoms including adrenocortical carcinoma, fever and flank pain. An important gene associated with Adrenal Cortical Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Insulin secretion. The drugs Bexxar and Perjeta have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal cortex and adrenal gland, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and behavior/neurological

Disease Ontology : 12 An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has material basis in abnormally proliferating cells derives from epithelial cells.

OMIM : 54 Adrenocortical carcinoma (ADCC) is a rare but aggressive childhood tumor, representing about 0.4% of childhood tumors,... (202300) more...

UniProtKB/Swiss-Prot : 66 Adrenocortical carcinoma: A malignant neoplasm of the adrenal cortex and a rare childhood tumor. It occurs with increased frequency in patients with Beckwith-Wiedemann syndrome and Li-Fraumeni syndrome.

Wikipedia : 71 Adrenocortical carcinoma, also adrenal cortical carcinoma (ACC) and adrenal cortex cancer, is an... more...

Related Diseases for Adrenal Cortical Carcinoma

Diseases related to Adrenal Cortical Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 136)
id Related Disease Score Top Affiliating Genes
1 adrenocortical carcinoma with pure aldosterone hypersecretion 11.9
2 adrenal carcinoma 11.6
3 li-fraumeni syndrome 11.5
4 salivary gland adenoid cystic carcinoma 11.5
5 aplasia cutis congenita, nonsyndromic 11.4
6 corpus callosum agenesis 11.1
7 agenesis of the corpus callosum with peripheral neuropathy 11.0
8 proud syndrome 10.9
9 adrenal cortical adenocarcinoma 10.8
10 ceruminous carcinoma 10.8
11 acinar cell carcinoma of pancreas 10.8
12 acetyl-coa carboxylase deficiency 10.7
13 aicardi syndrome 10.7
14 aplasia cutis congenita 10.7
15 aplasia cutis congenita with intestinal lymphangiectasia 10.7
16 acantholytic squamous cell skin carcinoma 10.3 IGF2 TP53
17 acinar cell carcinoma 10.3 HSD11B2 TP53
18 classic congenital mesoblastic nephroma 10.3 CHGA TP53
19 submucosal invasive colon adenocarcinoma 10.2 CHGA IGF2 TP53
20 cytomegalovirus retinitis 10.2 NR5A1 STAR
21 familial nasal acilia 10.2 CHGA CYP11B2 HSD11B2
22 adult medulloblastoma 10.2 CHGA CYP17A1 TP53
23 peroneal nerve paralysis 10.2 CHGA SYP
24 distal monosomy 14q 10.2 CYP11A1 CYP21A2
25 thymus small cell carcinoma 10.2 CHGA SYP
26 brain stem ependymoma 10.2 CHGA SYP
27 non specific chronic endometritis 10.2 CHGA SYP
28 extrahepatic biliary papillomatosis 10.2 CHGA SYP
29 prolactin producing pituitary tumor 10.2 CHGA SYP
30 epithelioid malignant peripheral nerve sheath tumor 10.2 CHGA SYP
31 cartilage cancer 10.2 CHGA SYP
32 villous adenocarcinoma 10.1 CHGA SYP
33 jejunal neuroendocrine tumor 10.1 CHGA SYP
34 renal pelvis adenocarcinoma 10.1 CHGA SYP
35 spasmodic dysphonia 10.1 CHGA SYP
36 cervical benign neoplasm 10.1 SYP TP53
37 x-linked sideroblastic anemia with ataxia 10.1 CYP11A1 CYP17A1 STAR
38 barre-lieou syndrome 10.1 CHGA SYP
39 perineural angioma 10.1 CHGA SYP TP53
40 exudative glomerulonephritis 10.1 CHGA SYP TP53
41 fragile x-associated tremor/ataxia syndrome 10.1 CHGA SYP TP53
42 brain stem astrocytic neoplasm 10.1 CHGA SYP TP53
43 thymus squamous cell carcinoma 10.1 CHGA SYP TP53
44 microinvasive cervical squamous cell carcinoma 10.1 CHGA SYP
45 growth retardation hydrocephaly lung hypoplasia 10.1 CHGA SYP TP53
46 blood group incompatibility 10.1 IGF2 SYP TP53
47 clear cell variant infiltrating bladder urothelial carcinoma 10.1 CHGA SYP TP53
48 adenoiditis 10.1
49 inner ear cancer 10.1 CHGA SYP TP53
50 dyt1 early-onset isolated dystonia 10.1 CYP17A1 CYP21A2

Graphical network of the top 20 diseases related to Adrenal Cortical Carcinoma:



Diseases related to Adrenal Cortical Carcinoma

Symptoms & Phenotypes for Adrenal Cortical Carcinoma

Symptoms by clinical synopsis from OMIM:

202300

Clinical features from OMIM:

202300

Human phenotypes related to Adrenal Cortical Carcinoma:

32
id Description HPO Frequency HPO Source Accession
1 adrenocortical carcinoma 32 HP:0006744

UMLS symptoms related to Adrenal Cortical Carcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.47 CYP21A2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.47 CYP21A2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.47 NR5A1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.47 CYP21A2 NR5A1 TP53 CYP11A1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 9.47 TP53
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.47 CYP11A1 CYP21A2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.47 CYP21A2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.47 CYP21A2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 9.47 CYP11A1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-62 9.47 TP53

Drugs & Therapeutics for Adrenal Cortical Carcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Bexxar 17 46 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa Approved June 2003
2
Perjeta 17 46 PERTUZUMAB Genentech Approved June 2012
3
Unituxin 17 46 DINUTUXIMAB United Therapeutics Approved March 2015
4
Portazza 17 NECITUMUMAB Eli Lilly Approved November 2015

Drugs for Adrenal Cortical Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Phase 1 51-43-4 5816
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Mitotane Approved Phase 3,Phase 2 53-19-0 4211
6
Streptozocin Approved Phase 3 18883-66-4 29327
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754 657311
9
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
10
Etomidate Approved Phase 2, Phase 3,Phase 1 33125-97-2 36339 667484
11
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
12
Lenograstim Approved Phase 3 135968-09-1
13
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538
14
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
15 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
16 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
17 Epinephryl borate Phase 3,Phase 2,Phase 1
18 Racepinephrine Phase 3,Phase 2,Phase 1
19 insulin Phase 3,Phase 2
20 Insulin, Globin Zinc Phase 3,Phase 2
21 Mitogens Phase 3,Phase 2
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Hormonal Phase 3,Phase 2
25 Etoposide phosphate Phase 3,Phase 2
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Adjuvants, Anesthesia Phase 3
28 Analgesics Phase 3
29 Analgesics, Opioid Phase 3
30 Anesthetics Phase 3,Phase 2,Phase 1
31 Anesthetics, General Phase 3,Phase 2,Phase 1
32 Anesthetics, Intravenous Phase 3,Phase 2,Phase 1
33 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
34 Narcotics Phase 3
35 pancreatic polypeptide Phase 3,Phase 1
36 Peripheral Nervous System Agents Phase 3,Phase 2
37 Adrenocorticotropic Hormone Phase 3,Phase 2
38 beta-endorphin Phase 3
39 Contraceptive Agents Phase 3,Phase 2
40 Contraceptives, Oral Phase 3
41 Contraceptives, Postcoital Phase 3
42 Cortisol succinate Phase 3,Phase 2
43 Hormone Antagonists Phase 3,Phase 2
44 Hormones Phase 3,Phase 2
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
46 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
47 Hydrocortisone acetate Phase 3,Phase 2
48 Luteolytic Agents Phase 3
49 Melanocyte-Stimulating Hormones Phase 3
50 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 66)
id Name Status NCT ID Phase
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3
2 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
4 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3
5 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3
6 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3
7 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3
8 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Active, not recruiting NCT00304070 Phase 3
9 Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Not yet recruiting NCT02010957 Phase 2, Phase 3
10 Sunitinib in Refractory Adrenocortical Carcinoma Unknown status NCT00453895 Phase 2
11 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2
12 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Unknown status NCT00003453 Phase 2
13 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
14 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2
15 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2
16 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2
17 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2
18 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2
19 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2
20 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2
21 A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2
22 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2
23 A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent Completed NCT00264433 Phase 2
24 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
25 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
26 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2
27 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2
28 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Recruiting NCT02673333 Phase 2
29 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2
30 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
31 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
32 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Recruiting NCT02804750 Phase 2
33 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Active, not recruiting NCT01833832 Phase 2
34 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2
35 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Active, not recruiting NCT02720484 Phase 2
36 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Not yet recruiting NCT03127774 Phase 2
37 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Not yet recruiting NCT02867592 Phase 2
38 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2
39 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2
40 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2
41 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1
42 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1
43 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1
44 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
45 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1
46 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
47 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
48 Spectroscopy With Surface Coils and Decoupling Completed NCT00581815 Phase 1
49 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Recruiting NCT01898715 Phase 1
50 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Recruiting NCT01772004 Phase 1

Search NIH Clinical Center for Adrenal Cortical Carcinoma

Cochrane evidence based reviews: adrenocortical carcinoma

Genetic Tests for Adrenal Cortical Carcinoma

Genetic tests related to Adrenal Cortical Carcinoma:

id Genetic test Affiliating Genes
1 Adrenocortical Carcinoma, Hereditary 29
2 Adrenocortical Carcinoma 29
3 Neoplasm of the Adrenal Cortex 29
4 Adrenocortical Carcinoma, Pediatric 29

Anatomical Context for Adrenal Cortical Carcinoma

MalaCards organs/tissues related to Adrenal Cortical Carcinoma:

39
Cortex, Adrenal Cortex, Adrenal Gland, Testes, Kidney, Lung, Breast

Publications for Adrenal Cortical Carcinoma

Articles related to Adrenal Cortical Carcinoma:

(show all 48)
id Title Authors Year
1
Giant adrenal cortical carcinoma. ( 28065533 )
2017
2
Adrenal cortical carcinoma with tumor thrombus extension into the right atrium: A case report. ( 27313728 )
2016
3
Peritoneal metastases from adrenal cortical carcinoma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( 27716880 )
2016
4
Mammary development, hyperestrogenemia, and hypocortisolemia in a male cat with an adrenal cortical carcinoma. ( 27708447 )
2016
5
Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma. ( 27857836 )
2016
6
Metastatic adrenal cortical carcinoma to T12 vertebrae. ( 26765762 )
2016
7
An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. ( 26685085 )
2016
8
Clinicopathological Features Associated With the Prognosis of Patients With Adrenal Cortical Carcinoma: Usefulness of the Ki-67 Index. ( 27227935 )
2016
9
Nonislet Cell Tumor Hypoglycemia in a Patient with Adrenal Cortical Carcinoma. ( 27957352 )
2016
10
Epithelioid angiomyolipoma mimicking adrenal cortical carcinoma: A diagnostic pitfall. ( 26622807 )
2015
11
Impact of Regional Lymph Node Dissection on Disease Specific Survival in Adrenal Cortical Carcinoma. ( 25938888 )
2015
12
Conditional survival among patients with adrenal cortical carcinoma determined using a national population-based surveillance, epidemiology, and end results registry. ( 26510907 )
2015
13
A Mimic of Sarcomatoid Adrenal Cortical Carcinoma: Epithelioid Angiosarcoma Occurring in Adrenal Cortical Adenoma. ( 25246132 )
2014
14
Aldosterone and cortisol co-secreting bifunctional adrenal cortical carcinoma: A rare event. ( 25097323 )
2014
15
"Dominant" myelolipoma encasing adrenal cortical carcinoma: an unusual variation of myelolipoma occurring as a synchronous and predominant neoplasm. ( 24788531 )
2014
16
Aldosterone-secreting adrenal cortical carcinoma. A case report and review of the literature. ( 24682757 )
2014
17
Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. ( 24102952 )
2014
18
Adrenal cortical carcinoma mimicking early severe preeclampsia. ( 27512421 )
2014
19
Resection of giant adrenal cortical carcinoma: a case report. ( 25582906 )
2014
20
Adrenal cortical adenoma with the maximal diameter greater than 5 cm: can they be differentiated from adrenal cortical carcinoma by CT? ( 25419344 )
2014
21
Adrenal cortical carcinoma with extension into the inferior vena cava--case report and literature review. ( 24602387 )
2014
22
Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. ( 24615603 )
2014
23
Adrenal cortical carcinoma in a child, a rare cause of paediatric endocrinopathy: case report and literature review. ( 23025626 )
2013
24
Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence. ( 23444945 )
2013
25
Primary hyperaldostronisim as initial presentation of adrenal cortical carcinoma with liver metastasis: a case report. ( 24505527 )
2013
26
Adrenal cortical carcinoma in Thailand: a review on the previous reported case. ( 24369210 )
2013
27
Adrenal cortical carcinoma with late pulmonary metastases causing clinicical Cushing's syndrome: case report with immunohistochemical analysis of steriodogenic enzyme production. ( 22784838 )
2012
28
Adrenal cortical carcinoma masquerading as pheochromocytoma: a case report. ( 23152728 )
2012
29
Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants. ( 22086150 )
2012
30
Carney complex with adrenal cortical carcinoma. ( 22112809 )
2012
31
Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure. ( 21648293 )
2011
32
Giant adrenal cortical carcinoma. ( 21196637 )
2011
33
Myxoid adrenal cortical carcinoma presenting as primary hyperaldosteronism: case report and review of the literature. ( 20444728 )
2011
34
Hyperaldosteronism and hyperprogesteronism in a cat with an adrenal cortical carcinoma. ( 15954552 )
2005
35
Myxoid adrenal cortical carcinoma--a rare variant of adrenocortical carcinoma. ( 16340152 )
2005
36
Non-functioning adrenal cortical carcinoma presenting with metastasis to the tongue. ( 12581389 )
2003
37
Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. ( 12472285 )
2002
38
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. ( 12236151 )
2002
39
Use of electron microscopic evaluation for the diagnosis of adrenal cortical carcinoma in fine needle aspiration cytology: a case report and review of the literature. ( 11793196 )
2001
40
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. ( 11481490 )
2001
41
Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma. ( 10509802 )
1999
42
Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma. ( 7978053 )
1994
43
Primary hyperaldosteronism: due to adrenal cortical carcinoma. ( 8323523 )
1993
44
Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma. ( 1581233 )
1992
45
Pure primary hyperaldosteronism due to adrenal cortical carcinoma. ( 4025371 )
1985
46
Pure primary hyperaldosteronism due to adrenal cortical carcinoma. ( 6375367 )
1984
47
Adrenal cortical carcinoma: an unusual cause of hyperaldosteronism. ( 6351990 )
1983
48
In vivo and in vitro studies of steroid production by a luteoma and an adrenal cortical carcinoma in mice. ( 4304996 )
1969

Variations for Adrenal Cortical Carcinoma

ClinVar genetic disease variations for Adrenal Cortical Carcinoma:

6 (show top 50) (show all 58)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
2 TP53 NM_000546.5(TP53): c.1010G> A (p.Arg337His) single nucleotide variant Pathogenic rs121912664 GRCh37 Chromosome 17, 7574017: 7574017
3 TP53 NM_000546.5(TP53): c.854A> T (p.Glu285Val) single nucleotide variant Pathogenic rs121912667 GRCh37 Chromosome 17, 7577084: 7577084
4 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
5 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
6 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
7 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
8 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
9 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
10 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
11 CTNNB1 NM_001904.3(CTNNB1): c.122C> T (p.Thr41Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913413 GRCh37 Chromosome 3, 41266125: 41266125
12 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
13 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh37 Chromosome 3, 41266136: 41266136
14 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
15 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
16 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
17 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
18 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
19 TP53 NM_000546.5(TP53): c.404G> A (p.Cys135Tyr) single nucleotide variant Likely pathogenic rs587781991 GRCh37 Chromosome 17, 7578526: 7578526
20 GNAS NM_000516.5(GNAS): c.602G> T (p.Arg201Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
21 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
22 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
23 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
24 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
25 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
26 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
27 CTNNB1 NM_001904.3(CTNNB1): c.134C> A (p.Ser45Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
28 BRAF NM_004333.4(BRAF): c.1780G> C (p.Asp594His) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
29 TP53 NM_001126112.2(TP53): c.518T> G (p.Val173Gly) single nucleotide variant Likely pathogenic rs1057519747 GRCh37 Chromosome 17, 7578412: 7578412
30 TP53 NM_001126113.2(TP53): c.518T> C (p.Val173Ala) single nucleotide variant Likely pathogenic rs1057519747 GRCh37 Chromosome 17, 7578412: 7578412
31 CTNNB1 NM_001904.3(CTNNB1): c.100G> C (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh37 Chromosome 3, 41266103: 41266103
32 CTNNB1 NM_001904.3(CTNNB1): c.134C> G (p.Ser45Cys) single nucleotide variant Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
33 CTNNB1 NM_001904.3(CTNNB1): c.101G> C (p.Gly34Ala) single nucleotide variant Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
34 CTNNB1 NM_001904.3(CTNNB1): c.122C> A (p.Thr41Asn) single nucleotide variant Likely pathogenic rs121913413 GRCh38 Chromosome 3, 41224634: 41224634
35 H3F3A NM_002107.4(H3F3A): c.100G> C (p.Gly34Arg) single nucleotide variant Likely pathogenic rs1057519902 GRCh37 Chromosome 1, 226252152: 226252152
36 PIK3CA NM_006218.3(PIK3CA): c.3141T> G (p.His1047Gln) single nucleotide variant Likely pathogenic rs1057519932 GRCh37 Chromosome 3, 178952086: 178952086
37 TP53 NM_001126113.2(TP53): c.404G> T (p.Cys135Phe) single nucleotide variant Likely pathogenic rs587781991 GRCh37 Chromosome 17, 7578526: 7578526
38 TP53 NM_001126116.1(TP53): c.7T> C (p.Cys3Arg) single nucleotide variant Likely pathogenic rs1057519975 GRCh37 Chromosome 17, 7578527: 7578527
39 TP53 NM_001126118.1(TP53): c.286T> A (p.Cys96Ser) single nucleotide variant Likely pathogenic rs1057519975 GRCh37 Chromosome 17, 7578527: 7578527
40 TP53 NM_001126113.2(TP53): c.403T> G (p.Cys135Gly) single nucleotide variant Likely pathogenic rs1057519975 GRCh37 Chromosome 17, 7578527: 7578527
41 TP53 NM_001126117.1(TP53): c.428G> T (p.Cys143Phe) single nucleotide variant Likely pathogenic rs863224451 GRCh37 Chromosome 17, 7577114: 7577114
42 TP53 NM_001126112.2(TP53): c.824G> C (p.Cys275Ser) single nucleotide variant Likely pathogenic rs863224451 GRCh37 Chromosome 17, 7577114: 7577114
43 TP53 NM_001126112.2(TP53): c.823T> C (p.Cys275Arg) single nucleotide variant Likely pathogenic rs1057519983 GRCh37 Chromosome 17, 7577115: 7577115
44 TP53 NM_000546.5(TP53): c.396G> C (p.Lys132Asn) single nucleotide variant Likely pathogenic rs866775781 GRCh37 Chromosome 17, 7578534: 7578534
45 TP53 NM_001126112.2(TP53): c.395A> C (p.Lys132Thr) single nucleotide variant Likely pathogenic rs1057519996 GRCh37 Chromosome 17, 7578535: 7578535
46 TP53 NM_001126112.2(TP53): c.394A> C (p.Lys132Gln) single nucleotide variant Likely pathogenic rs747342068 GRCh37 Chromosome 17, 7578536: 7578536
47 TP53 NM_000546.5(TP53): c.395A> T (p.Lys132Met) single nucleotide variant Likely pathogenic rs1057519996 GRCh37 Chromosome 17, 7578535: 7578535
48 TP53 NM_001126114.2(TP53): c.638G> T (p.Arg213Leu) single nucleotide variant Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
49 TP53 NM_001126112.2(TP53): c.637C> G (p.Arg213Gly) single nucleotide variant Likely pathogenic rs397516436 GRCh37 Chromosome 17, 7578212: 7578212
50 TP53 NM_001126112.2(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120

Cosmic variations for Adrenal Cortical Carcinoma:

9 (show top 50) (show all 73)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10801 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.404G>A p.C135Y 10
2 COSM11071 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1009C>T p.R337C 10
3 COSM44175 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.644G>C p.S215T 10
4 COSM43931 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.523C>A p.R175S 10
5 COSM11286 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1015G>T p.E339* 10
6 COSM4445249 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.808C>A p.L270M 10
7 COSM4445248 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1132G>T p.E378* 10
8 COSM4445247 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.812G>C p.G271A 10
9 COSM4445246 MED12 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.4857G>T p.K1619N 10
10 COSM5664 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.121A>G p.T41A 10
11 COSM5672 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.94G>A p.D32N 10
12 COSM5669 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.98C>T p.S33F 10
13 COSM4440759 APC adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.232G>T p.D78Y 10
14 COSM10659 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.817C>T p.R273C 9
15 COSM6815 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.461G>T p.G154V 9
16 COSM10645 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.527G>T p.C176F 9
17 COSM44083 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1036G>T p.E346* 9
18 COSM43755 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.833C>A p.P278H 9
19 COSM11245 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.430C>T p.Q144* 9
20 COSM10648 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.524G>A p.R175H 9
21 COSM10790 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.455C>T p.P152L 9
22 COSM10725 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.701A>G p.Y234C 9
23 COSM44623 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.487T>A p.Y163N 9
24 COSM44091 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.746G>A p.R249K 9
25 COSM44816 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.667C>T p.P223S 9
26 COSM44288 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.452C>T p.P151L 9
27 COSM44081 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1073A>T p.E358V 9
28 COSM107991 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1051A>G p.K351E 9
29 COSM11066 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.578A>T p.H193L 9
30 COSM11524 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.730G>T p.G244C 9
31 COSM43963 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.396G>C p.K132N 9
32 COSM10911 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.847C>T p.R283C 9
33 COSM10722 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.853G>A p.E285K 9
34 COSM326321 RB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producing c.1994T>G p.L665R 9
35 COSM584 NRAS adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.182A>G p.Q61R 9
36 COSM574 NRAS adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.38G>T p.G13V 9
37 COSM28933 NRAS adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.48A>C p.K16N 9
38 COSM4169851 MSH2 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1760-2A>G p.? 9
39 COSM1561683 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.125G>A p.G42D 9
40 COSM4445250 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1336C>T p.R446C 9
41 COSM23054 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.512G>A p.R171Q 9
42 COSM1355797 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.989G>A p.R330H 9
43 COSM23055 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.378G>A p.W126* 9
44 COSM4445245 MED12 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.5576G>A p.R1859H 9
45 COSM4445244 MED12 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.5530C>G p.Q1844E 9
46 COSM516 KRAS adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.34G>T p.G12C 9
47 COSM1684718 KCNJ5 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.503T>G p.L168R 9
48 COSM27887 GNAS adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.601C>T p.R201C 9
49 COSM28930 EGFR adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.2354C>A p.T785N 9
50 COSM13432 EGFR adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.2193G>A p.W731* 9

Copy number variations for Adrenal Cortical Carcinoma from CNVD:

7 (show all 23)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39293 10 11285212 16864223 Deletion Adrenocortical carcinoma
2 41923 10 26030462 27568983 Deletion Adrenocortical carcinoma
3 69267 12 54496959 54887816 Amplification Adrenocortical carcinoma
4 105388 16 79195214 80590034 Amplification Adrenocortical carcinoma
5 105796 16 82774218 84680399 Amplification Adrenocortical carcinoma
6 106027 16 85171711 86599633 Amplification Adrenocortical carcinoma
7 106330 16 87455812 88254372 Amplification Adrenocortical carcinoma
8 110643 17 33805634 34663603 Deletion Adrenocortical carcinoma
9 125811 19 15352798 16118051 Deletion Adrenocortical carcinoma
10 129302 19 45108448 45718366 Deletion Adrenocortical carcinoma
11 130528 19 49537470 50323207 Deletion Adrenocortical carcinoma
12 130657 19 50358143 53057498 Deletion Adrenocortical carcinoma
13 131131 19 53210832 53917176 Deletion Adrenocortical carcinoma
14 169573 3 142987765 144031265 Deletion Adrenocortical carcinoma
15 176088 3 46534671 47516603 Deletion Adrenocortical carcinoma
16 176572 3 49687490 50219610 Deletion Adrenocortical carcinoma
17 177057 3 52432656 53876467 Deletion Adrenocortical carcinoma
18 216378 6 91152410 95641352 Deletion Adrenocortical carcinoma
19 222196 7 150275058 151470304 Amplification Adrenocortical carcinoma
20 235763 8 144753570 146201712 Deletion Adrenocortical carcinoma
21 237149 8 21408650 22539377 Deletion Adrenocortical carcinoma
22 238033 8 29147511 31607545 Deletion Adrenocortical carcinoma
23 239018 8 36481039 39128088 Deletion Adrenocortical carcinoma

Expression for Adrenal Cortical Carcinoma

Search GEO for disease gene expression data for Adrenal Cortical Carcinoma.

Pathways for Adrenal Cortical Carcinoma

Pathways related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2
2
Show member pathways
12.16 CYP11A1 CYP11B2 CYP21A2 MC2R STAR
3 11.59 CYP11A1 CYP11B1 CYP21A2 STAR
4
Show member pathways
11.31 CYP11B1 CYP17A1 CYP19A1
5
Show member pathways
11.31 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2
6 11.26 CYP11A1 CYP17A1 CYP19A1 STAR
7
Show member pathways
11.17 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2
8
Show member pathways
10.78 CYP11B1 CYP11B2 CYP17A1 CYP21A2

GO Terms for Adrenal Cortical Carcinoma

Cellular components related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrial membrane GO:0031966 8.8 CYP11A1 CYP11B1 CYP11B2

Biological processes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.91 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2
2 steroid metabolic process GO:0008202 9.72 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP21A2
3 female gonad development GO:0008585 9.57 CYP19A1 NR5A1
4 regulation of neuronal synaptic plasticity GO:0048168 9.56 STAR SYP
5 C21-steroid hormone biosynthetic process GO:0006700 9.56 CYP11A1 CYP11B1 CYP11B2 STAR
6 estrogen biosynthetic process GO:0006703 9.55 CYP19A1 STAR
7 cellular response to potassium ion GO:0035865 9.54 CYP11B1 CYP11B2
8 regulation of steroid biosynthetic process GO:0050810 9.52 NR5A1 STAR
9 testosterone biosynthetic process GO:0061370 9.51 CYP19A1 STAR
10 glucocorticoid metabolic process GO:0008211 9.49 HSD11B2 STAR
11 mineralocorticoid biosynthetic process GO:0006705 9.48 CYP11B2 CYP21A2
12 aldosterone biosynthetic process GO:0032342 9.46 CYP11B1 CYP11B2
13 glucocorticoid biosynthetic process GO:0006704 9.46 CYP11B1 CYP17A1 CYP21A2 HSD11B2
14 cortisol biosynthetic process GO:0034651 9.43 CYP11B1 CYP11B2
15 sterol metabolic process GO:0016125 9.43 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2
16 regulation of blood volume by renal aldosterone GO:0002017 9.4 CYP11B2 HSD11B2
17 steroid biosynthetic process GO:0006694 9.17 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2

Molecular functions related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.8 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2
2 iron ion binding GO:0005506 9.63 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2
3 steroid hydroxylase activity GO:0008395 9.5 CYP11B2 CYP19A1 CYP21A2
4 heme binding GO:0020037 9.43 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2
5 corticosterone 18-monooxygenase activity GO:0047783 9.4 CYP11B1 CYP11B2
6 steroid 11-beta-monooxygenase activity GO:0004507 9.37 CYP11B1 CYP11B2
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.1 CYP11A1 CYP11B1 CYP11B2 CYP17A1 CYP19A1 CYP21A2

Sources for Adrenal Cortical Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....